<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4723">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04402801</url>
  </required_header>
  <id_info>
    <org_study_id>22327</org_study_id>
    <nct_id>NCT04402801</nct_id>
  </id_info>
  <brief_title>Patient Outcomes of Clinic Transition From Face to Face Encounter to Telemedicine in Cystic Fibrosis</brief_title>
  <official_title>Impact on Patient Outcomes of Clinic Transition From Face to Face Encounters to Telemedicine in the Cystic Fibrosis (CF) Adult Population at UVA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult patients with Cystic Fibrosis who are seen at the specialty CF clinic at University of&#xD;
      Virginia will be given an option to utilize telemedicine instead of in-person visits for&#xD;
      standard clinic visits. Health information from standard of care visits including FEV1,&#xD;
      exacerbations, leading to oral or intravenous antibiotics, laboratory results,&#xD;
      hospitalization records, and responses to health questionnaires will be recorded for research&#xD;
      purposes. Data collected for the research study will be compared to baseline and previous&#xD;
      years to determine if there are any deleterious effects for those who transition to&#xD;
      telemedicine clinic visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 stability</measure>
    <time_frame>12 months</time_frame>
    <description>A change of 10% or more in FEV1 percent predicted will be considered significant; FEV1 pre and pos covid telemedicine implementation will be compared</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exacerbation rate</measure>
    <time_frame>12 months</time_frame>
    <description>Exacerbation rate pre and pos covid telemedicine implementation will be compared</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Standard of Care Telemedicine Cohort</arm_group_label>
    <description>This cohort will have telemedicine visits in lieu of in-person clinic visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care In-Person Cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult CF patients 18 yo and older.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (18-year-old and older) with CF seen in the UVA adult CF clinic who&#xD;
             agree to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who cannot consent to the research study. In addition, prisoners will not be&#xD;
             included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dana Albon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Dana Albon, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

